Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsBristol Myers Squibb's Growth Portfolio sales rose 15% in the second quarter, and management raised its 2026 revenue guidance to $49 billion to $50 billion.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.